Abstract: The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.
Abstract: Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.
Type:
Grant
Filed:
February 27, 2018
Date of Patent:
April 11, 2023
Assignees:
Caerus Therapeutics, Inc., University of Georgia Research Foundation, Inc.
Abstract: Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.
Type:
Application
Filed:
February 27, 2018
Publication date:
December 2, 2021
Applicants:
CAERUS THERAPEUTICS, INC., UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.